Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

17.39B

Market cap17.39B

Price-Earnings ratio

10.62

Price-Earnings ratio10.62

Dividend yield

—

Dividend yield—

Average volume

1.53M

Average volume1.53M

High today

$119.62

High today$119.62

Low today

$117.14

Low today$117.14

Open price

$119.13

Open price$119.13

Volume

1.50M

Volume1.50M

52 Week high

$238.00

52 Week high$238.00

52 Week low

$110.04

52 Week low$110.04

BIIB News

TipRanks 3d

Strategic Collaborations and Financial Adjustments Bolster Biogen’s Growth Potential: A Buy Rating Justified

William Blair analyst Myles Minter has maintained their bullish stance on BIIB stock, giving a Buy rating on April 21. Myles Minter’s rating is based on severa...

TipRanks 5d

Biogen’s Strategic Focus and Market Positioning Justify Hold Rating Amid Uncertainties

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on April 17. Thomas Shrader has given his Hold rating due t...

Simply Wall St 6d

Biogen shareholders have endured a 61% loss from investing in the stock five years ago

Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. Zooming in on an example, the Biogen Inc. ( )...

Analyst ratings

54%

of 37 ratings

Buy

45.9%

Hold

54.1%

Sell